Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
InMode Ltd. stock logo
INMD
InMode
$14.94
+0.1%
$14.47
$13.14
$19.85
$944.36M21.11 million shs1.65 million shs
LivaNova PLC stock logo
LIVN
LivaNova
$56.37
+1.7%
$47.75
$32.48
$57.35
$3.08B0.96774,202 shs472,571 shs
Envista Holdings Corporation stock logo
NVST
Envista
$21.15
-0.5%
$20.29
$14.22
$23.00
$3.51B0.991.88 million shs1.04 million shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$67.67
-1.1%
$80.58
$41.50
$90.32
$3.60B-2.711.63 million shs923,265 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
InMode Ltd. stock logo
INMD
InMode
0.00%+0.88%+8.73%+4.11%-10.59%
LivaNova PLC stock logo
LIVN
LivaNova
0.00%+0.84%+37.05%+29.85%+11.87%
Envista Holdings Corporation stock logo
NVST
Envista
0.00%-2.42%+1.76%+16.89%+15.80%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.00%-1.31%-21.31%-10.56%+38.24%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
InMode Ltd. stock logo
INMD
InMode
2.2005 of 5 stars
2.12.00.00.03.71.71.9
LivaNova PLC stock logo
LIVN
LivaNova
1.5271 of 5 stars
1.53.00.00.03.51.71.3
Envista Holdings Corporation stock logo
NVST
Envista
4.0547 of 5 stars
2.23.00.03.82.90.03.1
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
4.4991 of 5 stars
4.51.00.04.62.82.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
InMode Ltd. stock logo
INMD
InMode
2.13
Hold$18.0420.76% Upside
LivaNova PLC stock logo
LIVN
LivaNova
3.00
Buy$59.715.93% Upside
Envista Holdings Corporation stock logo
NVST
Envista
2.33
Hold$20.92-1.05% Downside
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3.08
Buy$115.0970.08% Upside

Current Analyst Ratings Breakdown

Latest INMD, SLNO, NVST, and LIVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$106.00
8/21/2025
LivaNova PLC stock logo
LIVN
LivaNova
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$55.00 ➝ $58.00
8/20/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$123.00
8/18/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$100.00 ➝ $110.00
8/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$97.00 ➝ $106.00
8/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$105.00 ➝ $110.00
8/1/2025
Envista Holdings Corporation stock logo
NVST
Envista
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$24.00 ➝ $25.00
8/1/2025
Envista Holdings Corporation stock logo
NVST
Envista
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderperform ➝ Underperform$15.00 ➝ $18.00
8/1/2025
Envista Holdings Corporation stock logo
NVST
Envista
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$17.00 ➝ $19.00
8/1/2025
Envista Holdings Corporation stock logo
NVST
Envista
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $17.00
(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
InMode Ltd. stock logo
INMD
InMode
$394.82M2.39$1.82 per share8.19$10.12 per share1.48
LivaNova PLC stock logo
LIVN
LivaNova
$1.31B2.35$4.24 per share13.29$24.31 per share2.32
Envista Holdings Corporation stock logo
NVST
Envista
$2.55B1.38$1.66 per share12.75$17.05 per share1.24
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/A$5.68 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
InMode Ltd. stock logo
INMD
InMode
$181.27M$2.476.058.21N/A44.50%18.38%16.35%10/29/2025 (Estimated)
LivaNova PLC stock logo
LIVN
LivaNova
$63.23M-$3.89N/A17.95N/A-16.13%14.57%6.91%10/29/2025 (Estimated)
Envista Holdings Corporation stock logo
NVST
Envista
-$1.12B$0.3266.0817.481.132.11%4.84%2.68%10/29/2025 (Estimated)
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$175.85M-$4.14N/AN/AN/AN/A-73.74%-56.67%11/5/2025 (Estimated)

Latest INMD, SLNO, NVST, and LIVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
LivaNova PLC stock logo
LIVN
LivaNova
$0.84$1.05+$0.21$0.50$332.20 million$352.50 million
8/6/2025Q2 2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$0.53-$0.09+$0.44-$0.09$3.91 million$32.66 million
7/31/2025Q2 2025
Envista Holdings Corporation stock logo
NVST
Envista
$0.24$0.26+$0.02$0.16$638.21 million$682.10 million
7/30/2025Q2 2025
InMode Ltd. stock logo
INMD
InMode
$0.50$0.47-$0.03$0.42$98.45 million$95.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
InMode Ltd. stock logo
INMD
InMode
N/AN/AN/AN/AN/A
LivaNova PLC stock logo
LIVN
LivaNova
N/AN/AN/AN/AN/A
Envista Holdings Corporation stock logo
NVST
Envista
N/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
InMode Ltd. stock logo
INMD
InMode
N/A
9.60
8.58
LivaNova PLC stock logo
LIVN
LivaNova
0.31
1.29
1.09
Envista Holdings Corporation stock logo
NVST
Envista
0.46
2.44
2.08
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.21
15.13
15.01

Institutional Ownership

CompanyInstitutional Ownership
InMode Ltd. stock logo
INMD
InMode
68.04%
LivaNova PLC stock logo
LIVN
LivaNova
97.64%
Envista Holdings Corporation stock logo
NVST
Envista
N/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
97.42%

Insider Ownership

CompanyInsider Ownership
InMode Ltd. stock logo
INMD
InMode
6.92%
LivaNova PLC stock logo
LIVN
LivaNova
0.29%
Envista Holdings Corporation stock logo
NVST
Envista
0.66%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
6.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
InMode Ltd. stock logo
INMD
InMode
48063.21 million58.84 millionOptionable
LivaNova PLC stock logo
LIVN
LivaNova
2,90054.60 million54.44 millionOptionable
Envista Holdings Corporation stock logo
NVST
Envista
12,700166.18 million165.09 millionOptionable
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3053.15 million49.74 millionOptionable

Recent News About These Companies

Soleno Therapeutics, Inc. $SLNO Shares Bought by Siren L.L.C.
Guggenheim Reaffirms "Buy" Rating for Soleno Therapeutics (NASDAQ:SLNO)

New MarketBeat Followers Over Time

Media Sentiment Over Time

InMode stock logo

InMode NASDAQ:INMD

$14.94 +0.02 (+0.13%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$14.92 -0.03 (-0.17%)
As of 08/29/2025 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

LivaNova stock logo

LivaNova NASDAQ:LIVN

$56.37 +0.92 (+1.66%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$56.38 +0.01 (+0.01%)
As of 08/29/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

Envista stock logo

Envista NYSE:NVST

$21.14 -0.11 (-0.49%)
Closing price 08/29/2025 03:59 PM Eastern
Extended Trading
$21.18 +0.03 (+0.16%)
As of 08/29/2025 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

Soleno Therapeutics stock logo

Soleno Therapeutics NASDAQ:SLNO

$67.67 -0.74 (-1.08%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$67.19 -0.48 (-0.71%)
As of 08/29/2025 05:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.